Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

出版年份 2018 全文链接

标题

作者

关键词

出版物

JOURNAL OF CLINICAL ONCOLOGY

Volume 36, Issue 18_suppl, Pages LBA4-LBA4

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2018-06-08

DOI

10.1200/jco.2018.36.18_suppl.lba4

向作者/读者发起求助以获取更多资源

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

JOURNAL OF CLINICAL ONCOLOGY

向作者/读者发起求助以获取更多资源

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Become a Peeref-certified reviewer